Authors


Pam Sobotka

Latest:

Linking Leaders: Beyond the Boardroom

A view on redefining key roles across the evolving clinical development landscape.


Martin Robinson

Latest:

Is the New EU Clinical Trial Regulation 536/2014 Merely a Missed Opportunity?

The EU has announced a new regulation - number 536/2014 - for clinical trials, which is planned to come into force not before 28th May 2016. It is an important step because it sets out the requirements for a single clinical trial approval portal and the content of clinical trial applications to be standardized.


Janice Stack

Latest:

The Case for Universal GCP Education

The primary objectives of GCP are to protect the safety, rights, and welfare of subjects, and to ensure the credibility of trial data and resulting reports.


Peggy Schrammel

Latest:

Shifting the Large Simple Trials Paradigm

Conducting Large Simple Trials to answer questions about "real-world" medical interventions is not a recent concept.


Luizinha Monteiro

Latest:

Virtual CRA Meetings: Promoting Discussion, not Silence

Virtual CRA meetings hold a lot of potential, but work still needs to be done to ensure effectiveness.


Sy Pretorius, MD

Latest:

Trends in Clinical Development

Industry benefits from heightened innovation, site/sponsor relationships, and diversity.


James M. Davis

Latest:

Enhancing Trial Enrollment Through 'Goal Programming'

How iterative analysis of subject recruitment data can optimize outcomes during ongoing enrollment.



Michael Christel

Latest:

The Twists and Turns in Biopharma Dealmaking: 2024 Trends

A deep dive into the complex playing field for M&A and partnering pursuits in today’s increasingly make-or-break landscape for biopharma innovation.


Veronica Todaro, M.P.H.

Latest:

Patient Engagement in PD Research and Why It Matters

When we hear about a new blockbuster drug coming to market, we usually think about a medical treatment.


Ginny Payeur

Latest:

Decline of Trials in CEE: Fluctuation or Trend?

Examining why newly registered trials have fallen in Central and Eastern Europe, relative to other regions.


Maryanne Quinn

Latest:

TMF Reference Model Standard = Process Efficiency

One of the many activities across the clinical development cycle that is non-negotiable is the creation, collection, management, and storage of the documents that are contained in the Trial Master File.


Teri O'Donnell

Latest:

Impact on the Future

The use of RBM may be the only way forward as long as the development of medicines relies on clinical testing.


Michael A. Weber, MD

Latest:

Blood Pressure Evaluation During Early Phase Trials

A systematic approach for early identification of BP effects during development of new drugs.



Peter Malamis, MBA

Latest:

Getting to Clinical Trial Diversity

Differing levels of trust in clinical trials information channels across diverse populations is examined in this research.


Timothy Cho

Latest:

eSource Records in Clinical Research: Keeping it Simple

How to satisfy regulatory concerns about EDC data integrity and site controls over its source records.


Jeanne Green

Latest:

The Case for Universal GCP Education

The primary objectives of GCP are to protect the safety, rights, and welfare of subjects, and to ensure the credibility of trial data and resulting reports.


Christina Eberhart

Latest:

Academic Medical Centers Can Tackle CTMS Successfully

The excessive cost of clinical trials mixed with the inefficiency of clinical trial management is a widespread problem among research institutions.


Nick Darwall-Smith

Latest:

Shifting the Large Simple Trials Paradigm

Conducting Large Simple Trials to answer questions about "real-world" medical interventions is not a recent concept.


Dieter Baier, PhD

Latest:

An Ideal SOP System

A "can’t live with them, can’t live without them" attitude is revealed in survey of standard operating procedures in the management and conduct of clinical trials.


Gabriele B. Schmidt, PhD

Latest:

An Ideal SOP System

A "can’t live with them, can’t live without them" attitude is revealed in survey of standard operating procedures in the management and conduct of clinical trials.


Jamie Pearson

Latest:

Impact on the Future

The use of RBM may be the only way forward as long as the development of medicines relies on clinical testing.


Sean Neal

Latest:

Practical Thoughts on Common Standards: CDASH and E2B for Safety Reporting

Clinical research is complicated, and it?s not just the science. Take CDASH, CDISC and E2B for example. Aren?t acronyms awesome?


Kyle Ricketts

Latest:

The Importance of Detailed Patient Consent Tracking

Patient consent is important to stay on top of for many reasons.


Srini Dagalur

Latest:

CTMS: What You Should Know

The dilemma facing clinical operations executives when selecting a CTMS solution to manage clinical trials is to go with an existing approach/solution or explore alternative options.


Michael Herschel, MD

Latest:

SOPs in Clinical Research

Survey appraises the use of SOPs in clinical research from the sponsors' point of view.


Stephen Young

Latest:

Re-Branding "Risk-Based Monitoring" - A Call for "Targeted Site Quality Management"

With all of the buzz and excitement around risk-based monitoring, one might expect that the broad adoption of this emerging clinical research paradigm is well under way.


Dario Carrara

Latest:

Three-Pronged Approach to Optimizing Trial Monitoring

Study results using a quality-by-design method, risk-based monitoring, and real-time direct data entry.


Alison R. Manley

Latest:

Enhancing Trial Enrollment Through 'Goal Programming'

How iterative analysis of subject recruitment data can optimize outcomes during ongoing enrollment.

© 2025 MJH Life Sciences

All rights reserved.